BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1025
BMO Capital analyst Evan Kurtz maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $1001 to $1025.
Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
More than 300,000 people in the
FDA Approves Regeneron-Sanofi’s Sarilumab As First Biologic For Stiffness, Pain In Muscles
The FDA approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval…
Reported Late Tuesday Feb. 28, Regeneron Pharmaceuticals And Sanofi Announce Kevzara Approved By FDA As First And Only Biologic Indicated For Patients With Polymyalgia Rheumatica
Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial
Kevzara now approved to treat two chronic inflammatory disorders
TARRYTOWN, N.Y. and CAMBRIDGE,
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 5 years by 10.76% on an annualized basis…
Regeneron Says Pozelimab (C5 Antibody) BLA For Treatment Of Children And Adults With Ultra-rare CHAPLE Disease Accepted For FDA Priority Review
Regeneron announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pozelimab as a treatment for adults and children as young as 1 year of age with
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
Ocular Therapeutix Inc (NASDAQ:OCUL) announced interim 10-month data from its U.S. Phase 1 trial of OTX-TKI, axitinib intravitreal hydrogel implant for…
New Data Shows Roche’s Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
Roche Holdings AG (OTC:RHHBY) announced new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab) in macular…
EF Hutton Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $853
EF Hutton analyst Michael King maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $851 to $853.
SVB Leerink Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $834
SVB Leerink analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $770 to $834.